Dendritic cell cancer vaccine - ZhongSheng BioTech
Alternative Names: ZSNeo-DC1.1Latest Information Update: 10 Mar 2024
At a glance
- Originator Zhongsheng Kangyuan Biotechnology
- Class Antineoplastics; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioma
Most Recent Events
- 04 Feb 2024 Phase-I clinical trials in Glioma (Recurrent) in China (Parenteral) (NCT06253234)